Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nordic Randomized Phase III Trial of Two Different Durations of Adjuvant Therapy With Intermediate-dose Interferon Alfa-2b in Patients With High-risk Melanoma

NCT01259934 is registered in ClinicalTrials.gov with Karolinska Institutet as lead sponsor.

NCT NCT01259934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01259934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nordic Randomized Phase III Trial of Two Different Durations of Adjuvant Therapy With Intermediate-dose Interferon Alfa-2b in Patients With High-risk Melanoma
Lead sponsor
Karolinska Institutet
Phase
Phase 3
Overall status
Completed
Start date
November 30, 1996
Completion date
June 30, 2008
Enrollment
855 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant therapy, melanoma